Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report
Shuangxi Li, Rongrong Hu, De-liang Kong, Jing Xu, Qi Bian, Zhiyong Guo, Xiao-bin Mei
Abstract
Telitacicept, a B lymphocyte stimulator/A proliferation-inducing ligand dual-target fusion protein, mainly used for IgA nephropathy and systemic lupus erythematosus. We present two cases where adult patients with IgA vasculitis (IgAV) nephritis were successfully treated with Telitacicept, experienced no adverse reactions during the follow-up. Therefore, Telitacicept represents a promising additional treatment option for patients suffering from IgA vasculitis (IgAV).
Topics & Concepts
MedicineNephropathyVasculitisImmunologyNephritisImmunoglobulin ALupus nephritisAdverse effectGlomerulonephritisImmune systemInternal medicineKidneyImmunoglobulin GDiabetes mellitusEndocrinologyDiseaseRenal Diseases and GlomerulopathiesComplement system in diseasesVasculitis and related conditions